» Articles » PMID: 30117103

Targeting Axon Integrity to Prevent Chemotherapy-Induced Peripheral Neuropathy

Overview
Journal Mol Neurobiol
Date 2018 Aug 18
PMID 30117103
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is an irreversible off-target adverse effect of many chemotherapeutic agents such as paclitaxel, yet its mechanism is poorly understood and no preventative measure is available. CIPN is characterized by peripheral nerve damages resulting in permanent sensory function deficits. Our recent unbiased genome-wide analysis revealed that heat shock protein (Hsp) 27 is part of a transcriptional network induced by axonal injury and highly enriched for genes involved in adaptive neuronal responses, particularly axonal regeneration. To examine if Hsp27 could prevent the occurrence of CIPN, we first demonstrated that paclitaxel-induced allodynia was associated directly with axonal degeneration in sensory neurons in a mouse model of CIPN. We therefore hypothesize that by preventing axonal degeneration could prevent the development of CIPN. We drove expression of human Hsp27 (hHsp27) specifically in neurons. Development of mechanical and thermal allodynia was prevented completely in paclitaxel-treated hHsp27 transgenic mice. Strikingly, hHsp27 protected against paclitaxel-induced neurotoxicity in vivo including degeneration of afferent nerve fibers, demyelination, mitochondrial swelling, apoptosis, and restored sensory nerve action potential. Finally, we delineated signaling cascades that link CIPN development to caspase 3 and RhoA/cofilin activation in sensory neurons and peripheral nerves. hHsp27 exerted anti-apoptotic effect and maintained axon integrity by restoring caspase 3 and RhoA expression to basal levels. Taken together, our data suggest that by preventing axonal degeneration might prove beneficial as anti-CIPN drugs, which represents an emerging research area for therapeutic development.

Citing Articles

Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy.

Chen X, Gan Y, Au N, Ma C Front Mol Neurosci. 2024; 17:1345811.

PMID: 38660386 PMC: 11039947. DOI: 10.3389/fnmol.2024.1345811.


Real-time field-programmable gate array-based closed-loop deep brain stimulation platform targeting cerebellar circuitry rescues motor deficits in a mouse model of cerebellar ataxia.

Kumar G, Zhou Z, Wang Z, Kwan K, Tin C, Ma C CNS Neurosci Ther. 2024; 30(3):e14638.

PMID: 38488445 PMC: 10941591. DOI: 10.1111/cns.14638.


Endoplasmic reticular stress as an emerging therapeutic target for chronic pain: a narrative review.

Kim H, Lee D, Shen S Br J Anaesth. 2024; 132(4):707-724.

PMID: 38378384 PMC: 10925894. DOI: 10.1016/j.bja.2024.01.007.


Broad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy.

Lucarini E, Micheli L, Rajagopalan R, Ciampi C, Branca J, Pacini A Pain. 2023; 164(11):2581-2595.

PMID: 37556385 PMC: 10578426. DOI: 10.1097/j.pain.0000000000002963.


Protease-Activated Receptor 2 (PAR2) Expressed in Sensory Neurons Contributes to Signs of Pain and Neuropathy in Paclitaxel Treated Mice.

Kume M, Ahmad A, DeFea K, Vagner J, Dussor G, Boitano S J Pain. 2023; 24(11):1980-1993.

PMID: 37315729 PMC: 10615692. DOI: 10.1016/j.jpain.2023.06.006.


References
1.
Tezel G, Wax M . The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. J Neurosci. 2000; 20(10):3552-62. PMC: 6772694. View

2.
Decosterd I, Woolf C . Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 2000; 87(2):149-158. DOI: 10.1016/S0304-3959(00)00276-1. View

3.
Hilkens P, ven den Bent M . Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst. 1997; 2(4):350-61. View

4.
Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S . Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res. 2000; 60(19):5349-53. View

5.
Michaud L, Valero V, Hortobagyi G . Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000; 23(5):401-28. DOI: 10.2165/00002018-200023050-00005. View